2.5 THE EFFECT OF RENAL DENERVATION ON CENTRAL BLOOD PRESSURE AND ARTERIAL STIFFNESS IN TREATMENT RESISTANT ESSENTIAL HYPERTENSION: A SUBSTUDY OF A RANDOMIZED SHAM-CONTROLLED DOUBLE-BLINDED TRIAL (THE RESET TRIAL)

Autor: Christian D. Peters, Ole N. Mathiasen, Henrik Vase, Jesper Bech, Kent L. Christensen, Anne P. Schroeder, Ole Lederballe, Hans Rickers, Ulla Kampmann, Per L. Poulsen, Sten Langfeldt, Gratien Andersen, Klavs W. Hansen, Hans E. Bøtker, Morten Engholm, Jannik B. Bertelsen, Jens F. Lassen, Erling B. Pedersen, Anne Kaltoft, Niels H. Buus

Publikováno v: Artery Research, Vol 16 (2016)

Background: A recent sham-controlled trial (ReSET) showed no sustained effect of renal denervation (RDN) on 24-hour ambulatory blood pressure (24hA-BP) measurements in patients with treatment resistant hypertension.1 The aim of this substudy was to i

Externí odkaz: https://doaj.org/article/fb954618a46846a1a16558705d199897

Acute Effects of Tolvaptan on Renal Hemodynamics in Autosomal Dominant Polycystic Kidney Disease —A Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Renal Plasma Flow and Glomerular Filtration Rate

Autor: rgen Jensen, June Anita Ejlersen, Rikke Lund S oslash, nderbæk, rgaard Bech, Frank H Mose, Jesper N oslash, Erling B. Pedersen, My Helbo Malmberg, Jens J oslash

Publikováno v: Malmberg, M H, Mose, F H, Sønderbæk, R L, Ejlersen, J A, Jensen, J J, Pedersen, E B & Bech, J N 2019, ' Acute Effects of Tolvaptan on Renal Hemodynamics in Autosomal Dominant Polycystic Kidney Disease : A Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Renal Plasma Flow and Glomerular Filtration Rate ', Open Journal of Nephrology, vol. 9, no. 4, pp. 97-114 . https://doi.org/10.4236/ojneph.2019.94011

Background: Previous studies have shown that reduced renal plasma flow (RPF) may play a role in progression of renal disease in autosomal dominant polycystic kidney disease (ADPKD). Tolvaptan, a vasopressin 2 antagonist, reduces growth of total kidne

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541bf90ba1d1eada99a4b5e536ee123f
https://doi.org/10.4236/ojneph.2019.94011

Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects - a CASE control study

Autor: Jesper N. Bech, Frank H Mose, M. H. Malmberg, Erling B. Pedersen

Publikováno v: BMC Nephrology
BMC Nephrology, Vol 21, Iss 1, Pp 1-13 (2020)
Malmberg, M H, Mose, F H, Pedersen, E B & Bech, J N 2020, ' Urine concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects-a CASE control study ', BMC Nephrology, vol. 21, no. 1, 379 . https://doi.org/10.1186/s12882-020-02043-w

Background Concentration of the urine is primarily regulated via vasopressin dependent aquaporin-2 water channels in the apical membrane of kidney principal cells. It is unclear whether urine concentration ability in ADPKD differs from other patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5171e5984a48058e0420ff625611fe9
http://europepmc.org/articles/PMC7457520

Nocturnal Blood Pressure Decrease in Hypertensive Patients and Normotensives- Association with Obstructive Sleep Apnoea and Renal Function

Autor: Thomas G. Lauridsen, Nikolai Hoffmann-Petersen, Jeppe B. Rosenbaek, Erling B. Pedersen, Bodil G. Hornstrup, Jost Wessels, Jesper N. Bech, Pia H. Gjoerup

Publikováno v: Hornstrup, B G, Rosenbæk, J B, Hoffmann-Petersen, N, Gjørup, P H, Wessels, J, Lauridsen, T G, Pedersen, E B & Bech, J N 2018, ' Nocturnal Blood Pressure Decrease in Hypertensive Patients and Normotensives – Association with Obstructive Sleep Apnoea and Renal Function ', Open Hypertension Journal, vol. 10, pp. 28-40 . https://doi.org/10.2174/1876526201810010028

Background:Blunted nocturnal Blood Pressure (BP) decrease is seen in patients with hypertension and obstructive sleep apnoea (OSA). The influence of OSA and renal function on nocturnal BP decrease is not fully clarified.Objective:In this case control

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7fedb5f1690bd44838ba45ce9e09893
https://doi.org/10.2174/1876526201810010028

Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis

Autor: Magnus T. Jensen, Sören Möller, Jens P. Goetze, Flemming Bendtsen, Jesper N. Bech, Jens Otto Clemmesen, Fin Stolze Larsen, Rasmus Mogelvang, Troels M. Busk, Erling B. Pedersen, Jens S. Iversen, Jørgen Hjelm Poulsen

Publikováno v: Busk, T M, Bendtsen, F, Poulsen, J H, Clemmensen, J O, Larsen, F S, Gøtze, J P, Iversen, J S, Jensen, M T, Møgelvang, R, Pedersen, E B, Bech, J N & Møller, S 2018, ' Transjugular intrahepatic portosystemic shunt: Impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. ', American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 314, pp. G275-G286 . https://doi.org/10.1152/ajpgi.00094.2017

Transjugular intrahepatic portosystemic shunt (TIPS) alleviates portal hypertension and possibly increases central blood volume (CBV). Moreover, renal function often improves; however, its effects on cardiac function are unclear. The aims of our stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::912c149f973d71a9014c00653e452885
https://doi.org/10.1152/ajpgi.00094.2017